New chemo combo aims to boost survival in young ewing sarcoma patients

NCT ID NCT01864109

First seen Nov 12, 2025 · Last updated May 06, 2026 · Updated 28 times

Summary

This study adds two chemotherapy drugs, irinotecan and temozolomide, to the standard treatment for people aged 1 to 40 with newly diagnosed Ewing sarcoma. The goal is to see if this stronger combination can improve event-free survival by preventing the cancer from coming back or getting worse. Participants receive the added drugs alongside the usual five-drug regimen, surgery, and/or radiation therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.